MR-CHOP therapy (high dose MTX with R-CHOP) for primary CNS lymphoma.
Phase 2
- Conditions
- primary central nervous system lymphoma
- Registration Number
- JPRN-UMIN000020513
- Lead Sponsor
- Department of hematology and Immunology, Kanazawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1, extra CNS lesions 2, severe infectious disease 3, history of chemotherapy for lymphoma 4, HIV+, HTLV1+, HBs-Ag+ 5, judgement as inappropriate to inclusion to this study by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method